1
|
Butelet A, Poulain S, Jeanpierre E, Srour M, Nudel M, Chauvet P, Bauters A, Susen S, Dupont A, de Charette M. Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider. Leuk Lymphoma 2022; 63:3100-3104. [PMID: 36528585 DOI: 10.1080/10428194.2022.2113534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Ibrutinib, a first-class Bruton tyrosine kinase inhibitor, is known to be associated with adverse bleeding events and has been recently approved for the treatment of relapse Waldenström macroglobulinemia (WM). Here, we report the exhaustive clinical and biological follow-up of 2 patients treated by ibrutinib alone in the context of relapsed WM with an acquired von Willebrand syndrome (AVWS) complication. In two cases, ibrutinib has been shown to be quickly efficient and safe for treating both AVWS and its underlying condition the WM, without bleeding complications. Interestingly, ibrutinib treatment brings a rapid and extended over time normalization of von Willebrand factor clearance. These observations show that ibrutinib is a valuable therapeutic option in relapsed WM patients associated with AVWS and highlighting the need for further cohort studies with long-term follow-up of patients to confirm the efficacy and safety of a treatment by ibrutinib for WM patients with AVWS complication.
Collapse
Affiliation(s)
- Alexandre Butelet
- Hemostasis and transfusion department, Biology Pathology Center, University hospital of Lille, Lille, France
| | - Stéphanie Poulain
- Laboratory of Hematology, Biology Pathology Center, CHU of Lille, INSERM UMR-S 1177, Team 4, Cancer Research Institute, Univ. Lille, France
| | - Emmanuelle Jeanpierre
- Hemostasis and transfusion department, Biology Pathology Center, University hospital of Lille, Lille, France
| | - Micha Srour
- Service des Maladies du Sang, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Morgane Nudel
- Service des Maladies du Sang, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Paul Chauvet
- Service des Maladies du Sang, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Anne Bauters
- Hemostasis and transfusion department, Biology Pathology Center, University hospital of Lille, Lille, France
| | - Sophie Susen
- Hemostasis and transfusion department, Biology Pathology Center, University hospital of Lille, Lille, France
| | - Annabelle Dupont
- Hemostasis and transfusion department, Biology Pathology Center, University hospital of Lille, Lille, France
| | - Marie de Charette
- Service des Maladies du Sang, Centre Hospitalier Universitaire de Lille, Lille, France.,Service d'hématologie, Centre Hospitalier Universitaire de la Réunion, Saint Denis, France
| |
Collapse
|
2
|
Bortezomib/ibrutinib/rituximab. REACTIONS WEEKLY 2021. [PMCID: PMC8446156 DOI: 10.1007/s40278-021-02481-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|